Cargando…

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene

The lack of actionable mutations in patients with non‐small cell lung cancer (NSCLC) presents a significant hurdle in the design of targeted therapies for this disease. Here, we identify somatically mutated ABL1 as a genetic dependency that is required to maintain NSCLC cell survival. We demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Testoni, Ewelina, Stephenson, Natalie L, Torres‐Ayuso, Pedro, Marusiak, Anna A, Trotter, Eleanor W, Hudson, Andrew, Hodgkinson, Cassandra L, Morrow, Christopher J, Dive, Caroline, Brognard, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734836/ https://www.ncbi.nlm.nih.gov/pubmed/26758680 http://dx.doi.org/10.15252/emmm.201505456

Ejemplares similares

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
por: Marusiak, Anna A., et al.
Publicado: (2014)

Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets
por: Torres-Ayuso, Pedro, et al.
Publicado: (2019)

Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer
por: Torres-Ayuso, Pedro, et al.
Publicado: (2022)

Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin
por: Torres-Ayuso, Pedro, et al.
Publicado: (2018)

Autophagy is Essential to Suppress Cell Stress and to Allow BCR-Abl-Mediated Leukemogenesis
por: Altman, Brian J., et al.
Publicado: (2010)

Origin of the kink of somatic action potentials
por: Teleńczuk, Maria T, et al.
Publicado: (2015)

Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC
por: Guo, Ao-Xiang, et al.
Publicado: (2020)

Mixed Active and Passive, Heart Rate-Controlled Heat Acclimation Is Effective for Paralympic and Able-Bodied Triathletes
por: Stephenson, Ben T., et al.
Publicado: (2019)

Abl Is Able to Inhibit Cell Engulfment
por: Robinson, Richard
Publicado: (2009)

Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice
por: Vicente-Dueñas, Carolina, et al.
Publicado: (2012)

PReS-FINAL-2173: Protein kinase C delta deficiency is a new cause of monogenic SLE
por: Belot, A, et al.
Publicado: (2013)

Surgical Insights Are Essential to Integration of Immune Therapy in Resectable NSCLC
por: Donington, Jessica S.
Publicado: (2021)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

Local Actions of Melatonin in Somatic Cells of the Testis
por: Frungieri, Mónica Beatriz, et al.
Publicado: (2017)

Orange is the new black: Kinases are the new master regulators of tumor suppression
por: An, Elvira, et al.
Publicado: (2018)

BCR-ABL1-Associated Reduction of Beta Catenin Antagonist Chibby1 in Chronic Myeloid Leukemia
por: Leo, Elisa, et al.
Publicado: (2013)

Development of a circulating miRNA assay to monitor tumor burden: From mouse to man
por: Greystoke, Alastair, et al.
Publicado: (2015)

A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL
por: Rix, Uwe, et al.
Publicado: (2013)

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
por: Remon, Jordi, et al.
Publicado: (2020)

Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells
por: Marusiak, Anna A., et al.
Publicado: (2018)

New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases
por: Bensen, Ryan, et al.
Publicado: (2021)

Discrimination against differently abled children among rural communities in India: Need for action
por: Janardhana, N., et al.
Publicado: (2015)

c-Abl phosphorylation of ΔNp63α is critical for cell viability
por: Yuan, M, et al.
Publicado: (2010)

Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
por: Kim, So Yeon, et al.
Publicado: (2020)

The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
por: Persinger, Rasheda
Publicado: (2021)

Perfectly Able
por: International, Lighthouse
Publicado: (2010)

Affordance Matching Predictively Shapes the Perceptual Representation of Others’ Ongoing Actions
por: McDonough, Katrina L., et al.
Publicado: (2020)

ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination
por: Jones, Jill K, et al.
Publicado: (2023)

Induction of cell retraction by the combined actions of Abl–CrkII and Rho–ROCK1 signaling
por: Huang, XiaoDong, et al.
Publicado: (2008)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Ferroquine, an Ingenious Antimalarial Drug –Thoughts on the Mechanism of Action
por: Dubar, Faustine, et al.
Publicado: (2008)

The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors
por: Glowacki, Sylwester, et al.
Publicado: (2013)

CTCF Expression is Essential for Somatic Cell Viability and Protection Against Cancer
por: Bailey, Charles G, et al.
Publicado: (2018)

An Able Provincial Chairman
Publicado: (1913)

On Not Being Able to Paint
Publicado: (1951)

The Action of Mercury in Children
por: Stephenson, William
Publicado: (1871)

Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway
por: Sun, Yifeng, et al.
Publicado: (2014)

Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC
por: Crosbie, Phil A.J., et al.
Publicado: (2016)

Molecular BCR::ABL1 Quantification and ABL1 Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study
por: Marin, Anelis Maria, et al.
Publicado: (2023)

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
por: Ishii, Hidenobu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h6b762jblce2i9l0qdmes5ps8g